Intradiscal Nucleus Pulposus Allograft Versus Sham Procedure in Patients with Lumbar Discogenic Pain: A Randomized Clinical Trial
In brief
Nucleus pulposus allograft eased pain in 53% versus 5% after sham
In a randomized trial of 121 adults with chronic disc-related back pain, 53% receiving an allograft achieved at least a 30% pain reduction at three months, compared with 5% after sham. The six-month comparison is harder to interpret because most sham patients crossed over to treatment, and their earlier results were carried forward.
- Journal
- Journal of clinical medicine (Q1)
- Published
- 28 October 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Paul Verrills, Vahid Mohabbati, James Yu, Matthew Green, Daniel Bates, Harrison Mihailidis, et al.
- PMID
- 43030530
- DOI
- 10.3390/jcm15218389
Why clinicians should know about it
- Picked for Anesthesiology and Pain Medicine (paper of the day, 15 November 2026): Sham-controlled interventional trial for chronic discogenic back pain
Abstract
Background/Objectives: Chronic lumbar discogenic pain is a leading cause of disability. We evaluated the efficacy and safety of a single intradiscal injection of nucleus pulposus allograft compared with a sham procedure. Methods: Randomized, double-blind, sham-controlled superiority trial at five Australian pain centers. Adults with chronic lumbar discogenic pain were assigned 1:1 to allograft or sham. The prespecified primary endpoint was the proportion of participants with a ≥30% reduction in back pain visual analog scale (VAS) at 6 months. Sham non-responders could cross over to allograft treatment at 3 months; their 3-month values were carried forward to 6 months (last observation carried forward, LOCF). Results: A total of 121 participants were randomized (allograft 60, sham 61). At 3 months, the last visit at which both groups were fully observed, 53% (32/60) of allograft and 5% (3/60) of sham participants achieved the back pain responder threshold (difference 48 percentage points, 95% CI 33 to 61; p < 0.001). At 6 months, with LOCF for the 55 of 61 sham participants who crossed over, responder rates were 60% (36/60) versus 1.6% (1/61) (difference 58 percentage points, 95% CI 44 to 70; p < 0.001); superiority persisted in sensitivity analyses unless ≥45% of crossover participants would have responded untreated. Oswestry Disability Index responder rates were 53% versus 32% at 3 months and 60% versus 31% at 6 months (LOCF). Within 3 months, procedure- or product-related adverse events occurred in 6/60 (10%) allograft and 3/61 (5%) sham participants; two of these events were serious. Conclusions: Nucleus pulposus allograft produced large, clinically meaningful reductions in discogenic back pain compared with sham in the fully observed 3-month comparison. Most sham participants crossed over at three months as permitted by the protocol, and their three-month values were carried forward to the 6-month primary endpoint analysis. Registration: NCT06615505.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.